Shares of Travere Therapeutics Inc. (TVTX) are jumping on Tuesday after the company announced that its drug FILSPARI (sparsentan) has received full FDA approval for a rare kidney condition. The approval covers adult and pediatric patients aged 8 years and above, which is a big deal because it opens up treatment to a much wider group of people.
Travere is a biopharmaceutical company that focuses on rare kidney, liver, and metabolic diseases. The condition in question here is FSGS, which stands for focal segmental glomerulosclerosis. That's a mouthful, but basically it's a kidney disease where scarring happens in specific parts of the kidney's filtering units, leading to something called nephrotic syndrome. This causes protein to leak into the urine, swelling, high blood pressure, and can even lead to kidney failure.
What's really interesting about this approval is that it expands the potential patient population to over 100,000 individuals in the U.S. That includes more than 30,000 FSGS patients who don't have nephrotic syndrome. Until now, there wasn't an FDA-approved treatment for that group, so FILSPARI becomes the first and only option for them. That's a historic milestone—it's not every day a drug gets to claim "first and only" status.
In the Phase 3 DUPLEX Study, which was the largest head-to-head interventional study in FSGS to date, patients treated with FILSPARI in the overall study population saw a statistically significant 46% reduction in proteinuria from baseline to Week 108. That's compared to 30% for those treated with the maximum labeled dose of irbesartan, which was the comparator drug.
But here's where it gets even better: in patients without nephrotic syndrome, FILSPARI showed even greater improvements. Those patients experienced a 48% reduction in proteinuria from baseline to Week 108, compared to 27% for the irbesartan group. That difference was statistically significant, and FILSPARI-treated patients without nephrotic syndrome also demonstrated a benefit in eGFR, which is a measure of kidney function. So not only does it work, it works particularly well for the newly approved patient group.
On the stock side, Travere is having a great day. The stock is currently trading above its 20-day simple moving average by 52.7%, which indicates strong short-term momentum. It's also 39.4% above its 100-day SMA, suggesting the intermediate trend is bullish too. Over the past 12 months, the stock has gained 107.01%, showing strong investor confidence. Right now, it's trading near its 52-week high of $44.30, which points to solid upward momentum.
For traders watching the technicals, key resistance is at $44.50—that level might slow things down if the stock tries to push higher. On the flip side, key support is at $42.00, which could provide a floor if there's a pullback.
As of publication on Tuesday, Travere Therapeutics shares were up 37.12% at $42.09. The stock is trading near its 52-week high of $42.13, according to market data.
.jpeg)
